My Companies
Notification
Account
The U.S. Third Circuit affirmed summary judgment entirely in favour of Sun Pharmaceutical and subsidiaries in antitrust litigation concerning the 2008 generic Lipitor settlement with Pfizer, and upheld denial of class certification. The decision substantially closes the matter, subject to any further remedies available to plaintiffs.
Sun Pharma Wins US FDA Approval For Ilumya Psoriatic Arthritis Treatment
Sun Pharma Board To Consider Rs15,000 Crore NCD Issuance October 12
Sun Pharma Licenses Lerodalcibep From LIB Therapeutics For Ex-US China Markets
Sun Pharma Agrees U.S. MFN Pricing For Two-Year Tariff Delay